We work together with many local, national and international partners. Some of these are highlighted below.
Paul Hensbergen and his team at CPM have been instrumental in joint studies on protein abundance, proteolysis and post-translational modifications of C. difficile and other bacteria. We have been working together for over 10 years and regularly jointly supervise students. Some of the highlights of this collaboration include the identification of the first characterized Pro-Pro Endopeptidase, PPEP-1, and the elucidation of the pathway for the post-translational modification of flagellin.
Nathaniel Martin 's group is developing new drugs for the treatment of problematic bacteria. Our current collaboration focuses on the novel lipoglycopeptide antibiotic EVG7 in treatment of S.aureus and C. difficile infections.
The controlled human colonization and infection model for C. difficile is a close collaboration with the group of Meta Roestenberg (L-CHIC, InfectNL).
Together with the team of Marcela Krůtová we identify and characterize novel antimicrobial resistance mechanisms.
The activities as an expertise center for C. difficile infections benefit from long standing collaborations with the HCAI group in Leeds, UK (Mark Wilcox, Jane Freeman) as well as the Anaerobic Reference Unit (UKARU) in Cardiff, UK (Trefor Morris)
Our group also works together with industrial partners, such as Vedanta Biosciences and Acurx Pharmaceuticals.
